Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study

PURPOSE: To compare the efficacy and safety of ranibizumab 0.5 mg with or without verteporfin photodynamic therapy in Japanese patients with polypoidal choroidal vasculopathy over 12 months. STUDY DESIGN: EVEREST II was a 24-month, Phase IV, multicenter, randomized, double-masked study in Asian pati...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Ophthalmol
Päätekijät: Takahashi, Kanji, Ohji, Masahito, Terasaki, Hiroko, Honda, Shigeru, Margaron, Philippe, Guerin, Tadhg, Yuzawa, Mitsuko
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Dove Medical Press 2018
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6145359/
https://ncbi.nlm.nih.gov/pubmed/30271112
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OPTH.S171015
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia